Cas:702-77-2 1-Bromo-3-methyladamantane manufacturer & supplier

Chemical Name:1-Bromo-3-methyladamantane

CAS.NO:702-77-2

Synonyms:3-BROMO-1-METHYL-ADAMANTANE;Tricyclo[3.3.1.1]decane, 1-bromo-3-methyl-;1-bromo methyl-3 adamantane;1-Bromo-3-methyladamantane;1-Methyl-3-bromoadamantane;3-Methyl-adamantyl-(1)-bromid;1-bromo-3-methyl-adamantane;1-Methyl-3-bromadamantan;3-methyl-1-bromoadamantane

Molecular Formula:C₁₁H₁₇Br

Molecular Weight:229.157

HS Code:2903890090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:243.6±9.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.582

PSA:

Exact Mass:228.051361

LogP:4.51

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-BROMO-1-METHYL-ADAMANTANE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-methyl-1-bromoadamantane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Bromo-3-methyladamantane Use and application,1-bromo methyl-3 adamantane technical grade,usp/ep/jp grade.

Related News: Green Valley said it would launch the drug ��very soon�� in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug. 1-Bromo-3-methyladamantane manufacturer The drug, Imfinzi, when added to chemotherapy and the drugmaker��s other cancer drug tremelimumab, significantly improved the survival of patients without the disease progressing, when compared to chemotherapy alone, the company said. 1-Bromo-3-methyladamantane supplier Jo Soden, Co-managing Director of Retrogenix, said ��We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant��s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.�� 1-Bromo-3-methyladamantane vendor AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer. 1-Bromo-3-methyladamantane factory The drug, Imfinzi, when added to chemotherapy and the drugmaker��s other cancer drug tremelimumab, significantly improved the survival of patients without the disease progressing, when compared to chemotherapy alone, the company said.